Physician profile
Daniel Dawson
NPI 1659310779
$5,124.58
in general payments reported to CMS, 2019-2025
21 companies · $1,499 in 2025
The $1,499 reported for 2025 was more than what 85% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2021: $116 · 2022: $678 · 2023: $1,590 · 2024: $966 · 2025: $1,499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,054.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,054.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,254.26 | 2022-2025 | Vuity, Lumigan, Alphagan P |
| Alcon Vision LLC | $1,000.89 | 2019-2025 | Hydrus Microstent, Rocklatan, Clareon |
| Rxsight INC | $489.23 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Bausch & Lomb Americas INC. | $402.23 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Rayner Intraocular Lenses Limited | $345.77 | 2023-2025 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| Sight Sciences, INC. | $291.50 | 2019-2024 | Omni Surgical System |
| Glaukos Corporation | $274.69 | 2023-2025 | Ce-Marked Kxla System, Kxl System (Not Refurbished) |
| Sun Pharmaceutical Industries INC. | $210.50 | 2021-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $149.72 | 2025 | Xdemvy |
| Apellis Pharmaceuticals, INC. | $138.99 | 2024-2025 | Syfovre |
| Oyster Point Pharma, INC. | $99.46 | 2022-2025 | Tyrvaya, Ryzumvi |
| Omeros Corporation | $97.17 | 2019-2021 | |
| Iridex Corporation | $93.74 | 2022 | |
| Dompe US, INC. | $62.22 | 2024-2025 | Oxervate |
| Horizon Therapeutics Plc | $61.58 | 2022-2023 | Tepezza |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $44.63 | 2025 | Vevye |
| Ziemer USA | $28.02 | 2025 | Femtoldv |
| Amgen INC. | $23.10 | 2024 | Tepezza |
| Novartis Pharmaceuticals Corporation | $21.61 | 2023 | |
| Johnson & Johnson Surgical Vision, INC. | $21.18 | 2023 | Tecnis Iol |
| New World Medical,INC. | $14.09 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Dawson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.